Bob T. Li

机构：Memorial Sloan Kettering Cancer Center, NewYork–Presbyterian Hospital, Cornell University, New York Hospital Queens, Presbyterian Hospital, AstraZeneca (United States), Weill Cornell Medicine · ORCID：0000-0001-6661-8733

发表论文 608 篇 · 总被引 22211 次 · h-index 61

代表论文

• Homologous recombination deficiency and hemizygosity drive resistance in breast cancer (2026 · Nature · 被引 6)
• Monitoring of circulating tumor DNA in patients with stage II-III breast cancer treated with neoadjuvant chemotherapy (2026 · npj Breast Cancer · 被引 1)
• A Phase II Basket Trial of Ado-Trastuzumab Emtansine for Patients with HER2 -Amplified Cancers: A Nonrandomized Clinical Trial (2026 · Clinical Cancer Research)
• PTCH1 mutations and tumor-agnostic clinical outcomes with hedgehog pathway inhibitors across cancer types (2026 · npj Precision Oncology)
• Erratum: Resistance to Immune Checkpoint Inhibitor Treatment in Non–Small Cell Lung Cancer Clinical Trials: A Perspective From Lung-MAP Investigators (2026 · Journal of Clinical Oncology)
• Supplementary Figure S9 from Diverse ERBB2/ERBB3 Activating Alterations and Coalterations Have Implications for HER2/3-Targeted Therapies across Solid Tumors (2026)